It has been 20 years since the term “genome editing” first entered the scientific lexicon, a field that was revolutionized by the development of CRISPR gene editing in 2012. But the remarkable ...

The study, published in Nucleic Acids Research, introduces BLU-VIPR, a method that allows researchers to control the gene-editing tool CRISPR using light. This innovation could significantly ...

Under the terms of the arrangement, EditCo will incorporate Promega’s bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines. According to the partners ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

13. WASHINGTON — Keith Joung knows better than a lot of people what, exactly, it might require to prove to regulators and patients that CRISPR could be safely used to alter the genome of a human ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

To address this question, a new study used modern technology, called CRISPR interference, to systematically examine every gene in the human genome. The scientists identified a new set of genes ...

CRISPR Therapeutics has a 12-month low of $30.96 and a 12-month high of $67.88. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th.

April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic ...

In a secret location in the United States, two white wolves are lounging in the grass in a sunny, roughly one-acre enclosure. It’s early spring and a chill wind blows through bare trees nearby.